1 / 2

Article 82 and Predation: The (French) Glaxo Case

Article 82 and Predation: The (French) Glaxo Case. Konrad Stahl (Chair) Philippe Choné (CC Position) Michele Polo (Glaxo Position) Eric Avenel (Academic Position). Suggested points for discussion. What is the relevant market?

joelle-miller
Télécharger la présentation

Article 82 and Predation: The (French) Glaxo Case

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Article 82 and Predation:The (French) Glaxo Case Konrad Stahl (Chair) Philippe Choné (CC Position) Michele Polo (Glaxo Position) Eric Avenel (Academic Position)

  2. Suggested points for discussion • What is the relevant market? • What is the relevant measure for a predatory price (given that the TP can be subject to manipulation)? • Can the exit of Flavelab be assigned to anticompetitive practice? How about the exit of Lilly? • If it was, how about the strength of the signal, given the market penetration of Panpharma?

More Related